Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Completed · Phase 3

Conditions studied: Locally Advanced or Metastatic Unresectable Urothelial Cancer

In brief

The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

Key facts

Study ID
NCT04527991
Run by
Gilead Sciences
People needed
711
Starts
2021-01-13
Expected to finish
2025-07-04
Last updated by the study team
2026-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.